Dwarakanath B S
Division of Radiation Biosciences, Institute of Nuclear Medicine and Allied Sciences, New Delhi, India.
J Cancer Res Ther. 2009 Sep;5 Suppl 1:S27-31. doi: 10.4103/0973-1482.55137.
The glucose analog 2-deoxy-D-glucose (2-DG), an inhibitor of glucose transport and glycolytic ATP production, is the most widely investigated metabolic inhibitor for targeting glucose metabolism. Besides depleting energy in cells, 2-DG has also been found to alter N-linked glycosylation leading to unfolded protein responses and induce changes in gene expression and phosphorylation status of proteins involved in signaling, cell cycle control, DNA repair, calcium influx, and apoptosis. Inhibition of cell proliferation and induction of apoptosis have been observed as cytotoxic effects in a wide variety of tumor cells in vitro, while sensitization of tumor cells to ionizing radiation and certain chemotherapeutic drugs is associated with enhanced mitotic as well as apoptotic cell death induced by the primary therapeutic agent. Therefore, there has been a considerable amount of interest in developing 2-DG as a therapeutic agent or adjuvant in the radiotherapy and chemotherapy of tumors.
葡萄糖类似物2-脱氧-D-葡萄糖(2-DG)是一种葡萄糖转运和糖酵解ATP生成的抑制剂,是针对葡萄糖代谢进行研究最为广泛的代谢抑制剂。除了消耗细胞内的能量外,还发现2-DG会改变N-连接糖基化,导致未折叠蛋白反应,并诱导参与信号传导、细胞周期控制、DNA修复、钙内流和细胞凋亡的蛋白质的基因表达和磷酸化状态发生变化。在多种肿瘤细胞中,已观察到抑制细胞增殖和诱导细胞凋亡具有细胞毒性作用,而肿瘤细胞对电离辐射和某些化疗药物的敏感性增强与主要治疗剂诱导的有丝分裂以及凋亡性细胞死亡增加有关。因此,人们对开发2-DG作为肿瘤放疗和化疗的治疗剂或佐剂产生了浓厚兴趣。